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Although the neurobiological mechanisms underlying panic disorder (PD) are not yet clearly understood, increasing
amount of evidence from animal and human studies suggests that the amygdala, which plays a pivotal role in
neural network of fear and anxiety, has an important role in the pathogenesis of PD. This article aims to (1) review
the findings of structural, chemical, and functional neuroimaging studies on PD, (2) relate the amygdala to panic
attacks and PD development, (3) discuss the possible causes of amygdalar abnormalities in PD, (4) and suggest
directions for future research.
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Introduction
Panic disorder (PD) is characterized by repeated panic
attacks, often accompanied with anticipatory anxiety,
fear of losing control or sanity, or behavioral changes
related to the attacks [1]. An epidemiological study
conducted with a nationally representative sample
estimated the lifetime prevalence of PD to be 4.5% [2].
A panic attack typically develops suddenly and reaches
its peak within 10 minutes. Symptoms that accompany
panic attacks include palpitations, chest pain, sweating,
trembling, smothering, abdominal distress, dizziness,
and fear of dying. It is estimated to be highly preva-
lent, with the percentage of people who experience a
panic attack at least once in their lifetime reaching up
to 28.3% [2-4]. Panic responses, when proximal preda-
tory threat is approaching or is actually present, are
adaptive in the sense that they prepare animals to fight
vigorously or flee (“fight or flight response”) [5]. During
panic attacks, however, an intense fear response to
aroused sympathetic activity is manifested in the absence* Correspondence: inkylyoo@ewha.ac.kr
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reproduction in any medium, provided the orof actual danger [1]. Animal model studies, genetic stud-
ies, and human neuroendocrinology and neuroimaging
studies have provided important insights [5-9], although
the neurobiological underpinnings of the panic attack
and PD are not yet completely understood [10].
Neuroendocrinological studies have implicated dysfunc-
tion of the hypothalamic-pituitary-adrenal axis, although
this perturbation occurs only later in the course of the dis-
order, after the development of anticipatory anxiety and
associated distresses [11,12]. Apart from higher levels of
COMT Val158Met polymorphism in PD patients, the role
of genes in PD susceptibility has not yet been defined [7].
Neuroanatomical correlates that may be responsible
for PD pathogenesis have been suggested [6,13]. The
implicated brain areas are the amygdala, thalamus,
hypothalamus, and brain stem regions including the
periaqueductal gray, parabrachial nucleus, and locus
ceruleus [6,13]. In particular, the amygdala has been
suggested to have a critical role in PD [14], while there
have been a few studies that indicate otherwise [15].
The aim of this review is to describe and discuss the
neuroimaging findings and current hypotheses on the
role of amygdala in the pathophysiology of PD.The amygdala
The amygdala is known to have 13 nuclei, which can be
categorized into lateral, basal and central subregions. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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grouped as laterobasal subgroup including both lateral
and basal nuclei, centromedial subgroup, and cortical
subgroup. These subgroups deal with fear [17], a process
which can be schematically illustrated as follows: the lat-
eral subgroup receives information from the cortical and
subcortical areas, the basal subgroup inter-connects the
lateral and central subgroups, and sends the output to
the cortical areas, and the central subgroup conveys the
information to the brain regions including hypothalamus
and periaqueductal gray [17]. The laterobasal and central
subgroups are also connected with bed nucleus of the
stria terminalis, which also projects to hypothalamus,
cerebellum, and brain stem areas [18].
The Figure 1 shows the simplified inputs and outputs of
the amygdala, which have been reported to be associated
with PD pathogenesis [13,18]. Theoretically, disruption in
any of these brain areas and connections along these areas,
or any imbalance in the network can cause maladaptive
and exaggerated fear responses such as panic attacks,
increased basal anxiety or arousal [19], and excessive
worrying [18,20]. Consistent with this postulation, struc-
tural, chemical, and functional alterations in these
amygdalar areas have been reported in neuroimaging stud-
ies in patients with PD (Tables 1, 2, 3, 4, 5; Additional files
1, 2, 3). It has been suggested that the amygdala has a crit-
ical role in the development of panic attacks and the
pathogenesis of PD [14,17,18].
Structural abnormalities of the amygdala in patients
with PD
There have been only a handful of structural neuroimaging
studies that examined neuroanatomical alterations in
patients with PD (Tables 1, 2, Additional file 1), relative
to the number of studies in patients with other anxiety
disorders such as post-traumatic stress disorder and ob-
sessive compulsive disorder [42-45].Figure 1 Schematic diagram of inputs to and outputs from the amygIn earlier studies using the computerized tomography
(Table 1), it may have not been possible to evaluate
amygdalar structural alterations due to insufficient spatial
resolution and tissue contrast.
All magnetic resonance imaging studies in which
amygdalae were manually traced have consistently
reported amygdalar volume reduction in patients with
PD [46-48] (Additional file 1). In the report of Uchida
and colleagues, there was a trend-level significance for
bilateral amygdalar volume reduction [48], while two
other studies reported a statistically significant bilateral
amygdalar volume reduction [46,47]. In addition to the
relatively small sample size, the fact that amygdalae were
traced on 2 mm-thick reformatted magnetic resonance
(MR) images in the study of Uchida and colleagues [48]
may have resulted in a comparatively greater error range,
which could have undermined the power of detecting
volume differences of small structures. In the report of
Massana and colleagues, 1.2 mm-thick isocubically re-
formatted MR images were used for tracing [47]. Al-
though the voxel size of images used for tracing is not
described in the report of Hayano and colleagues [46], it
is likely that 1.5-mm thick native images were used
according to the standard protocol of manual segmenta-
tion in 3D slicer (http://www.slicer.org) which was the
image analysis software adopted in the study.
Among five studies that used whole brain-wise ap-
proach of voxel-based morphometry (VBM) (Additional
file 1), the report of Asami and colleagues noted
amygdalar volume reduction [49]. It has been suggested
that VBM approach may have limited sensitivity for
identifying a priori-specified structural differences un-
less analytical approaches such as small volume correc-
tion are applied. This indicates that a large sample size
may be required for the reliable results in VBM studies
[50-52]. Thus, it is not surprising that the study of
Asami et al., which had the positive finding in thedala, relevant to panic disorder pathogenesis.
Table 1 Structural neuroimaging findings in panic disorder [computerized tomography]
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n = 1; Beta blockers,








Not assessed Not assessed CT abnormalities:
Frontal CSF space▲










At some period treated
with psychotropic






hemispheres, n = 30
Not
assessed
Not assessed Not assessed CT abnormalities:
Cerebral atrophy,
n = 3; Lacunar
infarcts, n = 2;
Enlarged lateral
ventricles, n = 1























Table 2 Structural neuroimaging findings in panic disorder [diffusion tensor imaging]





















































HC 24 (10) 30.6 (5.1) - - - -























Table 3 Functional neuroimaging findings in panic disorder [near-infrared spectroscopy]
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Table 4 Functional neuroimaging findings in panic disorder [electroencephalography]













77 (0) None None None taking medication
No correlations between




Lepola, 1990 [22] PD 31 (23)
37 (Range
16–52)





Stein, 1989 [28] PD 35 (24) 35 (8)
n = 33 free of all psychotropic
drugs for a minumum of
2 weeks. n = 2 has taken a
low dose of a benzodiazepine
2 days before evaluation.
n = 5 (14%) had nonspecific
abnormal EEGs. None had
evidence supportive of an
ictal process.
Abbreviations: CCK-4, cholecystokinin tetrapeptide; EEG, electroencephalography; PD, panic disorder.
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VBM studies.
The effect size for group differences was greater in the
right amygdala than the left amygdala across all four
studies that have reported the amygdalar volume reduc-
tion [46-49]. In the study of Asami et al., a statistically
significant amygdalar volume reduction was noted only
in the right hemisphere. For the studies of Hayano et al.
and Uchida et al., Ray and Shadish’s equation 2 [53] was
used to compute Cohen’s d values based on t score and
sample sizes for each group presented in the paper
(Cohen’s d = 0.77 for the right amygdala; 0.60 for the left
amygdala in Hayano et al.; Cohen’s d = 0.78 for the right
amygdala [8% volume differences]; 0.76 for the left
amygdala [5% volume differences] in Uchida et al.).
Regarding the report of Massana et al., Cohen’s d for
amygdalar volume differences was 2.07 for the right
amygdala and 1.66 for the left amygdala.
Reasons for the potentially greater deficits in the right
amygdala than in the left amygdala in patients with PD
may be understood in a large body of literature on hemi-
spheric organization for processing emotions such as
fear. The right hemisphere has long been considered to
have dominance over the left hemisphere regarding
emotional behaviors [54,55]. Theories that suggest the
lateralized role of right and left hemispheres for different
aspects of emotions have arisen [56]. Sackeim and
colleagues proposed that the right hemisphere may have
dominance especially in processing negative emotions
[57]. Regarding fear processing and the amygdala, more
recent neuroimaging studies indicated that the right
amygdala is primarily involved in processing acquired
fear, while the left amygdala is particularly involved in
processing innate fear [58]. This lateralization has been
interpreted in the context that innate fear may require
more conscious and linguistic processing of the stimuli.
On the other hand, acquired fear may not require asmuch conscious elaborations of the stimuli since the re-
sponse would rather be automatic [58]. In PD, enhanced
conditionality of fear (i.e., a tendency to acquire fear
more easily) with resistance to extinction has been
considered as one of the core elements of the pathology
[59,60].
Because of the cross-sectional nature of the studies, it
is not appropriate to infer the causality of the relation-
ship between PD and reduced amygdalar volume. How-
ever, although speculative, some of the evidence
indicates that amygdalar deficits, particularly the deficit
in the right amygdala, may predispose to PD. Massana
and colleagues found that amygdalar volume reduction
was noted in both subgroups of PD patients with long
duration of illness (>6 months) and those with relatively
short duration of illness (<6 months). There were no
associations between the magnitude of amygdalar vol-
ume reduction and clinical measures including panic
symptom severity and illness duration [49]. In Uchida
et al., correlational results between amgydalar volume
and clinical measures were not reported [48]. In the
study of Hayano et al., the right amygdalar volume of
patients with PD had a negative correlation with the
neuroticism score of NEO personality inventory-revised,
the measure of enduring tendency toward experiencing
negative emotional states, while the left amygdalar vol-
ume showed a negative correlation with the state anxiety
score from the State-Trait Anxiety Inventory, the meas-
ure of anxiety severity [46]. This conjecture is entirely
speculative and subsequently urges further studies.
It is less likely that amygdalar deficits in patients with
PD are due to the use of antidepressants. The total daily
dose of antidepressant was not associated with the
amygdalar volume reduction [49]. The study of Massana
and colleagues was conducted in patients who are
antidepressant-naive [47]. Also, a meta-analysis in
patients with major depressive disorder has suggested
Table 5 Chemical neuroimaging findings in panic disorder [magnetic resonance spectroscopy]
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Abbreviations: API, Acute Panic Inventory; ASI, Anxiety Sensitivity Index; BDZ, benzodiazepine; Cho, choline; Cr, creatine; CRAS, Clinician-Rated Anxiety Scale; DM/DALPFC, dorsomedial/dorsal anteromedial prefrontal cortex; GABA,
gamma-aminobutyric acid; Glx, glutamte + glutamine; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; HC, healthy control; NAA, N-acetyl aspartate; PAS, Panic and Agoraphobia Scale; PCr,
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volume, rather than causing amygdalar deficits [61].
Since the amygdala is composed of many different
subnuclei with distinctive connections and functions
[62], researchers are interested in whether there would
be subregional specificity of the amygdalar deficit.
Hayano and colleagues investigated which subregion of
the amygdala might show more deficits in patients with
PD [46]. They employed the optimized voxel-based
morphometry with small volume correction using bilat-
eral amygdalar masks. Volume deficits were noted in the
amygdalar subregion that might correspond to the
corticomedial subregional group. Central and medial
subnuclei that are parts of the corticomedial subregion
have been implicated for autonomic responses to fear
stimuli [63]. However, the laterobasal subregion of the
amygdala has also been reported to be involved in the
pathogenesis of PD [64]. Further studies that adopt strat-
egies that may allow finer registration among inter-
subject amygdalae [65-67] may be needed to confirm the
subregional findings.
Evaluating the structural connectivity among the
amygdala and other brain regions on diffusion tensor
images would provide important additional information
[68]. Relative to healthy comparison subjects, patients
with PD had a greater fractional anisotropy value in the
left anterior and right posterior cingulate regions [23]
(Table 1). These regions may have a role in maintaining
visceromotor homeostasis through its interconnections
with the amygdala [69]. Recently, with the use of high
quality diffusion tensor images and T1-weighted images,
evaluating the connections among amygdalar subregions
and other brain regions has become possible [70,71].
Studies with this approach would also enhance the
understanding on the roles of amygdalar subregions.
Functional abnormalities of the amygdala in patients
with PD
Functional neuroimaging techniques that have been used
for studying PD include functional magnetic resonance
imaging (fMRI), positron emission tomography (PET),
single photon emission computed tomography (SPECT),
electroencephalography (EEG), and near-infrared spec-
troscopy (NIRS). Among these, NIRS and EEG may not
be suitable for assessing amygdalar activity due to a rela-
tively superficial penetration depth [72] (Tables 2 and 4).
There have been PET and SPECT studies that used
neutral state paradigms. Earlier studies with a region-
of-interest approach did not find significantly different
amygdalar activity [73-75] (Additional file 2). As De
Cristofaro and colleagues commented [74], image
resolutions of SPECT and PET may not be sufficient for
delineating the amygdala from other adjacent structures.
A neutral-state PET study which used a whole brain-wiseapproach [76] also did not find amygdalar metabolic
differences, while in a more recent study [77], a greater
metabolism in bilateral amygdalar regions was noted in
patients with PD compared with healthy comparison
subjects. The authors conjectured that this discrepancy
may have stemmed from differences in image resolution,
sample size, and subjects’ age [77].
Among three fMRI studies that captured brain re-
gional activation during spontaneous panic attacks, two
studies conducted in patients with PD or specific phobia
have found increased right amygdalar activation [78,79].
A study conducted in an individual with restless leg syn-
drome but without any history of psychiatric disorders
has noted the relationship of the left amygdalar activity
and the heart rate [80] (Additional file 3). A PET study
could not find the difference of the amygdalar blood
flow in a healthy volunteer who experienced a panic at-
tack during fear conditioning in comparison with 5
healthy volunteers who did not experience panic attacks
during the same fear conditioning sessions [81].
Symptom provocation paradigms were used both in
healthy volunteers and in patients with PD (Additional
file 2, 3). When challenged with cholecystokinin
tetrapeptide (CCK-4) or procaine, healthy volunteers
showed increased amygdalar activation [82] or increased
regional cerebral blood flow [83-85]. In patients with
PD, CCK-4 or doxapram intravenous injection did not
elicit significantly greater amygdalar activation [86,87].
Due to relatively modest sample sizes, there is a risk for
the type II error, precluding the possibility of drawing
any conclusions from these negative findings. In a report
of Boshuisen et al., PD patients experiencing anticipatory
anxiety showed significantly decreased regional cerebral
blood flow in the right amygdala [88]. The authors
commented on the possibility that cortical inhibitory
effects in response to the intense anticipatory anxiety
may have depressed the amygdalar activity. It has also
been suggested that this might reflect the functional im-
pairment of the amygdala to cope with the anticipatory
anxiety [88].
Cognitive activation probes to evaluate amygdalar
function have been used in functional neuroimaging
studies of PD [9]. In most studies which used fMRI,
patients with PD showed altered amygdalar activation
level (Additional file 3) except a study with motor activa-
tion paradigms [89] and a few with a relatively small sam-
ple size [90,91]. In addition, Maddock et al., suggested that
repeated presentation of the threat-related stimuli in their
study (20 words being repeated eight times) may have
habituated the amygdalar response [90]. This may have
resulted in the negative finding in this region.
Among studies that report altered amygdalar activa-
tion in PD patient group relative to comparison group,
both higher and lower amygdalar activation level was
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amygdalar activation, two studies [93,94] noted deactivated
the amygdala in patients with PD relative to healthy com-
parison subjects. Statistical activation maps of comparison
between the threat condition vs. the safe condition in the
study of Tuescher and colleagues showed less activation in
the amygdala of PD patients in the threat condition relative
to post traumatic stress disorder patients [93]. However,
this was mainly due to amygdalar hyperactivation in PD
patients in the safe condition relative to threat condition,
while post-traumatic stress disorder patients showed
increased amygdalar activation in the threat condition. The
fact that patients with PD were compared to those with
post-traumatic stress disorder in this study, and the differ-
ence in the experimental paradigm from other studies
precludes direct comparison of this study result with those
from other studies [95]. In this study, patients were
instructed that visual presentation of the square with a cer-
tain color would mean that an electrodermal stimulation
can occur at any time. Actual stimulation did not happen
during scanning. This may have caused anticipatory anx-
iety as in the study of Boshuisen and colleagues [88], in
which patients with PD also exhibited decreased regional
cerebral blood flow in the amygdala. Deactivation of the
amygdala in response to presentation of fearful faces [94]
may in part be due to the facts that most of the patients
were taking antidepressants [92], since antidepressants
have been reported to decrease the amygdalar activity [96].
In addition, it should be considered that the relatively leni-
ent statistical threshold (p < 0.05) for a priori-hypothesized
regions of the anterior cingulate cortex and the amygdala
[94]. It is possible that only certain subgroups of patients
with PD exhibit amygdalar hyperactivation [92]. Only
women were responsive to fearful faces [97]. Patients with
the COMT 158 val allele showed hyperactivation of the
amygdala in response to fearful faces [98]. In a relatively
small sample size, the heterogeneity with regard to genetic
polymorphism and sex may make it hard to detect the
increased amygdalar activation, if any [99]. Baseline anxiety
and associated physiologic changes may also confound
functional neuroimaging findings [19].
Findings regarding laterality of amygdalar activation
(Additional file 3) are less consistent than those of
amygdalar volume (Additional file 1). Left and right
amygdalae are known to be involved in different aspects
of fear processing [58]. Direct comparison of results is
not appropriate since the experimental paradigms are
slightly different with each other [95]. In studies with a
relatively small sample size, differences in the number of
subjects with right or left-handedness may confound the
laterality findings [95].
There have been reports that investigated amygdalar
function in relation to the treatment (Additional file 2).
When untreated patients and treated patients werecompared with healthy comparison subjects, patients
treated with antidepressants showed no difference in
amygdalar serotonin binding potential, while untreated
patients showed significantly lower serotonin binding
potential [100]. Treatment with paroxetine for 12 weeks
in psychotropic medication-naive PD patients altered
amygdalar glucose metabolism [101]. In the report of
Prasko and colleagues, treatment with antidepressants
did not change the amygdalar glucose metabolism [102].
This may have stemmed from exposure to antidepressants
prior to study participation [102]. Cognitive behavioral
therapy did not change the amygdalar glucose metabolism
[102,103]. The number of studies in regards to treatment-
related changes in amygdalar function is small and more
studies are required for conclusions.
Potential mechanisms underlying altered amygdalar
function and structure in patients with PD
Structural and functional neuroimaging findings with
regard to the amygdala in patients with PD are not per-
fectly consistent, but a pattern suggested by one of the
neurocircuitry models may be noted [13]. Increased re-
activity of the amygdala with structural deficits, similar
to the findings in other anxiety disorders such as post-
traumatic stress disorder [92]. Whether structural
deficits of the amygdala cause its hyper-reactivity or
hyperactivation of the amygdala for a prolonged period
elicits overuse atrophy is not known [104].
Brain physiological processes underlying altered
amygdalar function and structure may be partly
expounded by the findings from molecular imaging and
chemical neuroimaging studies (Additional file 2,
Table 5). Decreased gamma amino-butyric acid (GABA)-
benzodiazepine receptor binding has been reported in
the medial temporal lobes that may include amygdalar
regions [105,106] (Additional file 2). In the amygdala,
decreased 5-HT1A receptor binding has also been
reported [100]. Both of these receptors are involved in
inhibitory neurotransmission. Defective inhibition of the
amygdalar activity may result in paroxysmal elevations
in anxiety [105]. Chemical neuroimaging studies have
reported lower levels of GABA in patients with PD than
healthy comparison subjects [37,40], which were not
reversed with acute benzodiazepine challenge [38].
Decreases in the GABA level may cause dysfunction in
GABAergic inhibition of brain activity [107]. Morever,
experimentally lowered GABA level caused panic-like
behaviors in rats [108].
Findings from chemical neuroimaging studies suggest
metabolic disturbances in the brain of patients with PD
[19] (Table 5). Hypermetabolic state was suspected based
on the findings that show depletion of phosphocreatine
and creatine [92,109] in patients with PD, consistent with
functional neuroimaging findings. Shioiri and colleagues
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with PD [41]. Inorganic phosphate is known to be
accumulated when creatine phosphate is broken down
during anaerobic metabolism [110]. A rapid rise of the
brain lactate level in response to physiological challenge
(vigilance task with visual stimuli) also suggests an intrinsic
metabolic disturbance [19,36].
Genetic polymorphism and early-life experiences may
also contribute to amygdalar abnormalities. Specially,
the COMT Val158Met polymorphism that affects the
amygdalar structure, function, and receptor expression
[98,111-113] has also been reported to be associated
with PD development [7].
Data from the National Comorbidity Survey showed
a positive association between early-life traumatic
experiences and later development of PD [114]. PD
patients who experienced early-life traumatic events
had more severe symptom profile [115]. Relationships
between early-life traumatic experiences and amygdalar
dysfunction have also been reported [116].
The role of amygdalar pathology in developing PD
Electrical or chemical stimulation of the amygdalar central
nucleus causes constellation of symptoms that are very
similar to those of panic attacks [63]. Electrolytic lesions
made in the central nucleus would also disrupt fibers
connecting laterobasal nucleus and bed nucleus of the stria
terminalis, which has outputs to the hypothalamus and
brain stem [18], where the centers for autonomic and
neuroendocrine response regulations are located. When
the efferent fibers from the central nucleus are stimulated,
similar effects are produced [117]. By abruptly blocking
the tonic GABAergic inhibition in the laterobasal sub-
region of the amygdala, symptoms mimicking panic
attacks are induced [64]. These animal studies suggest the
role of the amygdala in the pathogenesis of PD.
Earlier models to explain the neurobiology of PD have
underscored the hypersensitivity to carbon dioxide, namely
“false suffocation alarm theory [118,119],” although it has
been revised since [120]. The following neurocircuitry
model [13] is well suited for explaining the role of the
‘hyperactive and smaller’ amygdala [104] in the pathogen-
esis of PD for the fairly consistent findings.
Findings of Ziemann et al., suggest the role of the
amygdala in sensing central acidosis [121] which has
been considered as one of the core pathophysiological
processes in PD [122]. In chemical neuroimaging studies
in which neurometabolite changes were measured dur-
ing induced panic attacks [31-33,102], lactate/n-acetyl as-
partate level increased during panic attacks (Table 5).
Hyperventilation or sodium lactate infusion leads to a
metabolic alkalosis, which presumably augments neuronal
activity [123] and alters the redox state to glycolytic me-
tabolism producing lactate [29,31]. The report of Shioiriand colleagues which found increased level of inorganic
phosphate, a potential indicator of anaerobic metabolism,
indirectly supports the possibility of the redox shift to gly-
colysis [41]. It is also possible that lactate builds up pre-
sumably due to reduced cerebral blood flow [124].
Elevated brain lactate level, which would be associated
with decreased brain pH or exaggerated alkalotic buffering
[29], may trigger a panic attack by stimulating the amyg-
dala through the chemosensing ion channel [121].
The role of the amygdala in progression to PD
Panic attacks do not necessarily progress to PD [3].
Bouton and colleagues [60] proposed that among all
individuals who experience panic attacks, only those
who have increased conditionality would develop PD.
As panic attacks recur, the association would become
even stronger [125,126]. Consistent with this hypoth-
esis, enhanced conditionality [127] and resistance to ex-
tinction in patients with PD have been reported. Altered
anxiety neurocircuitry including the amygdala in PD
may in part be responsible for this enhanced condition-
ality and resistance to extinction.
The amygdala projects to the striatum and cortical
areas, and induce behavioral changes [62]. Phobic avoid-
ance or agoraphobia, often associated with PD, may re-
flect the amygdala’s influence on these areas [128].
Unlike the general belief that ’cognition rules over emo-
tion,’ there is evidence that emotion modulates cogni-
tion from perception and attention [17] to higher
domains of judgment and reasoning [129]. Irrational
worry about the connotation of the attacks, one of the
PD core symptoms, may also be partly attributed to the
amygdalar structural and functional abnormalities.
Summary and recommendations
The amygdala has been reported to have a crucial role in
the pathophysiology of PD. In animal studies, behaviors
similar to those of panic attacks were observed when the
amygdala was stimulated. Increased amygdalar activity with
volumetric deficits was noted in patients with PD, although
not always consistent. This altered function and structure
of the amygdala may be partly due to dysregulated brain
metabolism [31-33,121]. As potential causes of amygdalar
abnormality in PD, COMT Val158Met polymorphism and
early life traumatic experiences can also be suggested
[112,130,131].
Enhanced conditionality and resistance to extinction
are known as risk factors in progression from panic at-
tack to PD. As an important element of the anxiety
neurocircuitry, altered amygdalar function and structure
may facilitate the progression to PD. Typical PD
symptoms such as phobic avoidance and irrational worry
of panic attacks may also be attributed to amygdalar
structural and functional abnormalities.
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studies are possibly due to sample heterogeneity, small
sample size, and limitations of neuroimaging techniques.
More studies with a larger sample size are warranted. In
terms of technical difficulties, subregional analysis of the
amygdala, which detects alterations in subregions of the
amygdala separately, could be a novel strategy for future re-
search, since each nucleus might have a distinct role in the
pathophysiology of PD. This approach has already shown
its potential in structural neuroimaging studies [65,66] and
functional neuroimaging studies, examining neural circuitry
in healthy individuals [132,133]. A postmortem study, in-
vestigating association between pathology in amygdalar
subdivisions of patients with Parkinson’s disease [134] and
premortem anxiety symptoms, provides another insight for
a new strategy.
Conclusions
The amygdala, the hub of fear processing networks, is
closely associated with the pathogenesis of PD as well as
panic attack. Further studies in well-defined larger samples,
with more sophisticated research designs and advanced
technologies would promise a better understanding on the
role of the amygdala in the pathophysiology of PD.
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